BREAKING: Moderna receives FDA green light for COVID-19 booster targeting the Omicron variant
- Moderna’s Omicron-tailored COVID-19 booster shot has received emergency use authorization from the FDA for adults 18 and older
- Regulators have aimed to get the shots out to Americans by September, ahead of a potential fall surge of the virus
Moderna has received emergency use authorization from the Food and Drug Administration (FDA) for its Omicron-specific COVID-19 booster shot, the firm announced Wednesday.
The jab is the first reformulated shot to receive the regulatory green light in the U.S. It has been approved for all adults aged 18 and older. Pfizer, Moderna’s main competitor in the rollout of COVID-19 shots, is expected to receive similar approval soon as well.
The new shots will raise antibody protections against the Omicron variant – which includes all of the most infectious strains of the virus yet. Previous versions of the shot were tailored to the original Wuhan Covid strain, and the virus has since mutated to evade the protection they provided.
Regulators have aimed to get the shots out by September ahead of another potential spike in cases as the weather gets colder.
‘The FDA’s authorization of our updated bivalent booster, mRNA-1273.222, provides Americans with access to broader protection against Omicron variants,’ said Stéphane Bancel, CEO of Moderna, in a statement.
‘Receiving a booster that specifically targets the Omicron BA.4/.5 variant, currently the most prevalent strain of SARS-CoV-2, is an important public health measure that people can take to help protect themselves, especially as we head into a season filled with indoor gatherings.’